BiomX Wants To Reverse The Focus Of Microbiome Therapy
Executive Summary
Emerging Company Profile: Where other microbiome-focused firms seek to add bacteria to the patient's gut, Israel's BiomX thinks it can treat IBD and other conditions with phage therapies that subtract harmful microbiota.
You may also be interested in...
Finance Watch: Scripps Research Models A New Way To Fund Translation
Private Company Edition: Scripps Research has a new model for translating academic findings into drugs, including a novel fund for financing that work. Also, in venture capital deals, Oyster Point closes a $93m Series B round and Peloton raises a $150m Series E.
Antibiotic Development Question: Should A Phage Library Equal One Application?
FDA may have to take a personalized medicine approach when deciding how to classify a phage bank used to create the treatments.
How Intract Is Helping Shape Microbiome-Based Therapies
Bill Lindsay, CEO of University College London spin-out Intract Pharma, tells Scrip in an interview how the firm’s novel technologies are expected to play a key role in the effective delivery of microbiome-based therapies.